The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin.

The natural product withaferin A (WFA) exhibits antitumor and antiangiogenesis activity in vivo, which results from this drug's potent growth inhibitory activities. Here, we show that WFA binds to the intermediate filament (IF) protein, vimentin, by covalently modifying its cysteine residue, which is present in the highly conserved alpha-helical coiled coil 2B domain. WFA induces vimentin filaments to aggregate in vitro, an activity manifested in vivo as punctate cytoplasmic aggregates that colocalize vimentin and F-actin. WFA's potent dominant-negative effect on F-actin requires vimentin expression and induces apoptosis. Finally, we show that WFA-induced inhibition of capillary growth in a mouse model of corneal neovascularization is compromised in vimentin-deficient mice. These findings identify WFA as a chemical genetic probe of IF functions, and illuminate a potential molecular target for withanolide-based therapeutics for treating angioproliferative and malignant diseases.

[1]  U. Aebi,et al.  The biology of desmin filaments: how do mutations affect their structure, assembly, and organisation? , 2004, Journal of structural biology.

[2]  W. Franke,et al.  Characterization of disulfide crosslink formation of human vimentin at the dimer, tetramer, and intermediate filament levels. , 1996, Journal of structural biology.

[3]  H. Hammers,et al.  Withaferin A is a potent inhibitor of angiogenesis , 2004, Angiogenesis.

[4]  Nikhil V. Shirahatti,et al.  Actin microfilament aggregation induced by withaferin A is mediated by annexin II , 2006, Nature chemical biology.

[5]  J. Ambati,et al.  Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. , 2003, Investigative ophthalmology & visual science.

[6]  Yiider Tseng,et al.  A Direct Interaction between Actin and Vimentin Filaments Mediated by the Tail Domain of Vimentin* , 2006, Journal of Biological Chemistry.

[7]  C. Dass,et al.  In‐vitro and in‐vivo assays for angiogenesis‐modulating drug discovery and development , 2006, The Journal of pharmacy and pharmacology.

[8]  J. Markl,et al.  Vimentin and desmin of a cartilaginous fish, the shark Scyliorhinus stellaris: sequence, expression patterns and in vitro assembly. , 2001, European journal of cell biology.

[9]  T. Sejersen,et al.  Forced expression of desmin and desmin mutants in cultured cells: impact of myopathic missense mutations in the central coiled-coil domain on network formation. , 2006, Experimental cell research.

[10]  W. Franke,et al.  Identification of a distinct soluble subunit of an intermediate filament protein: tetrameric vimentin from living cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[11]  U. Aebi,et al.  Conserved segments 1A and 2B of the intermediate filament dimer: their atomic structures and role in filament assembly , 2002, The EMBO journal.

[12]  C. Crews,et al.  Chemical genetics: exploring and controlling cellular processes with chemical probes. , 1999, Trends in biochemical sciences.

[13]  W. Bornmann,et al.  The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Markovitz,et al.  Vimentin is secreted by activated macrophages , 2003, Nature Cell Biology.

[15]  R. Liem,et al.  Plakins: a family of versatile cytolinker proteins. , 2002, Trends in cell biology.

[16]  A. Bode,et al.  The Intermediate Filament Protein Vimentin Is a New Target for Epigallocatechin Gallate* , 2005, Journal of Biological Chemistry.

[17]  M. Bogyo,et al.  Activity-Based Protein Profiling , 2004, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[18]  C. Crews,et al.  Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. , 1999, Bioorganic & medicinal chemistry letters.

[19]  C. Crews,et al.  Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  K. Kim,et al.  Development of withaferin A analogs as probes of angiogenesis. , 2006, Bioorganic & medicinal chemistry letters.

[21]  W. Kao,et al.  Dynamics of the expression of cytoskeleton components and adherens molecules by fibroblastic cells in alkali-burned and lacerated corneas. , 1994, Experimental eye research.

[22]  A. Belldegrun,et al.  Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. , 2003, Cancer research.

[23]  S. Gitter,et al.  Antitumor activity of withaferin A (NSC-101088). , 1967, Cancer chemotherapy reports.

[24]  R. Evans,et al.  Tetracycline regulated expression of vimentin in fibroblasts derived from vimentin null mice. , 1997, Journal of cell science.

[25]  P. Bargagna-mohan,et al.  Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization. , 2006, Investigative ophthalmology & visual science.

[26]  Kaixian Chen,et al.  Virtual screening on natural products for discovering active compounds and target information. , 2003, Current medicinal chemistry.

[27]  C. Babinet,et al.  Mice lacking vimentin develop and reproduce without an obvious phenotype , 1994, Cell.

[28]  S. Schreiber.  Chemical genetics resulting from a passion for synthetic organic chemistry. , 1998, Bioorganic & medicinal chemistry.

[29]  A. W. Nicholas,et al.  Novel cytotoxic and antitumor agents. IV. Withaferin A: relation of its structure to the in vitro cytotoxic effects on P388 cells. , 1984, Neoplasma.

[30]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[31]  B. Lévy,et al.  Reduction of renal mass is lethal in mice lacking vimentin. Role of endothelin-nitric oxide imbalance. , 1997, The Journal of clinical investigation.

[32]  Paul Martin,et al.  Impaired wound healing in embryonic and adult mice lacking vimentin. , 2000, Journal of cell science.

[33]  Jinbao Liu,et al.  Impairment of the Ubiquitin-proteasome System in Desminopathy Mouse Hearts Clonal Hek Cell Lines Stably Expressing a Surrogate Ups Substrate (gfpu) , 2022 .

[34]  A. Griffioen,et al.  Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. , 2006, Blood.

[35]  A. Mara,et al.  A chemical and genetic approach to the mode of action of fumagillin. , 2006, Chemistry & biology.

[36]  P. Carmeliet,et al.  Under stress, the absence of intermediate filaments from Müller cells in the retina has structural and functional consequences , 2004, Journal of Cell Science.

[37]  V. Allan,et al.  Intermediate Filaments: Vimentin Moves in , 2002, Current Biology.

[38]  K. Biemann,et al.  Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. , 1997, Chemistry & biology.

[39]  P. Hordijk.  Endothelial signalling events during leukocyte transmigration , 2006, The FEBS journal.

[40]  Guoqing Shi,et al.  The Tumor Proteasome Is a Primary Target for the Natural Anticancer Compound Withaferin A Isolated from “Indian Winter Cherry” , 2007, Molecular Pharmacology.

[41]  A. Hamza,et al.  How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors. , 2006, The journal of physical chemistry. B.

[42]  S. Dagenais,et al.  Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. , 2000, Alternative medicine review : a journal of clinical therapeutic.